esomeprazol in treatment of gastroesophagial reflux disease in children and adolescents
Abstract
The results of trials of activity of esomeprazol in children with gastroesophagial reflux disease (gerd) are presented in this article. It was marked that esomeprazol (Nexium) can be used in children of 1–11 years (10 or 20 mg daily) and 12–17 years (20 or 40 mg daily) with gerd according to modern recommendations. The information about acid suppressor activity of esomeprazol in children with gerd younger then 2 years old (0,25–1 mg/kg daily) was published. Clinical activity of esomeprazol was confirmed in a number of randomized and open labeled, developed in different countries, including Russia. At the same time main results of activity of this medication were obtained in investigations of adult patients with gerd. This fact indicates necessity of provision of wide ranging trials, which could make complete assessment of advantages and safety profile of esomeprazol.
Key words: children, adolescents, gastroesophagial reflux disease, esomeprazol, treatment.
Key words: children, adolescents, gastroesophagial reflux disease, esomeprazol, treatment.
Keywords
Citation
ID:
162355
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
162355
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet